Answers are grounded in this paper and cite their sources.
Tools that enable functional inhibition of the long-term effects of immunological signalling cascades remain challenging to develop, in part because biological outcomes often arise long after the initiating receptor-ligand interaction and lack accessible experimental readouts. Interleukin-7 (IL-7) cytokine signalling through the IL-7 receptor (IL-7R) exemplifies this problem, as IL-7-mediated survival signals in activated CD4+ T cells emerge over extended timescales, yet play a critical role in human disease. Here, we describe the development of engineered Adhiron binders as molecular tools to inhibit IL-7/IL-7R signalling. Using phage display against glycosylated human IL-7Rα ectodomains, we isolated 23 unique Adhiron binders. From this panel, we identified a lead binder, Adh-42, that binds both soluble and membrane-associated IL-7Rα. Adh-42 inhibited proximal IL-7R signalling events in human cells and abrogated IL-7-mediated rescue from activation-induced cell death in human primary CD4+ T-cell blasts (using a recently developed in vitro assay). Together, these findings demonstrate that Adhiron binders can be used to target a cell-surface cytokine receptor (IL-7R) and selectively inhibit downstream biological outcomes in human primary cells. This work establishes Adhirons as versatile molecular tools for probing IL-7 cytokine signalling and provides a framework to support the design and evaluation of future therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Perez‐Witzke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: